DermTech Announces A few New Important Leadership Appointments: Chief Health-related Officer, Vice President, Revenue and Vice President, Information and facts Technological innovation and Digital Techniques

LA JOLLA, Calif.–(Business WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a chief in precision dermatology enabled by

LA JOLLA, Calif.–(Business WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a chief in precision dermatology enabled by a non-invasive skin genomics system, introduced now three new important management appointments: Loren Clarke, M.D. to the position of Main Health care Officer, Ray Bassi to the part of Vice President, Sales and Patrick Johnson to the part of Vice President, Details Technological know-how and Digital Devices.

Loren Clarke, M.D., is a board-qualified Pathologist and Dermatopathologist with comprehensive expertise in medical dermatopathology and molecular diagnostics. He succeeds Burkhard Jansen, M.D. who has taken on a new function as Main Clinical Affairs Officer capitalizing on his solid track record of doing work with payors, clinicians, and medical societies. Dr. Clarke joins DermTech from Myriad Genetics, Inc. in which he served as Senior Vice President for Health care Affairs and Professional medical Director for the Dermatology Division. Dr. Clarke has authored or co-authored more than 50 peer-reviewed publications, various guide chapters, and a textbook of Dermatopathology, and serves on the Editorial Board of the Journal of Cutaneous Pathology. He has acquired awards from the American Society for Clinical Oncology, the American Culture of Dermatopathology, the AOA Health care Honor Modern society, and the Arnold P. Gold Foundation’s award for Humanism and Excellence in Training. Dr. Clarke completed his health-related schooling and Residency in Pathology at the Penn Condition Hershey Health-related Center and a Fellowship in Dermatopathology at the College of Pennsylvania just before becoming a member of Penn Condition as school in the Division of Dermatopathology.

“I’m thrilled to welcome Loren to DermTech. Loren’s intensive encounter and believed management in scientific dermatopathology and genomic products growth in dermatology and pores and skin cancer will be a big asset to us in advancing our vision to guide the genomics revolution in skin health,” commented John Dobak, M.D., main executive officer of DermTech.

“I’m honored to guide the Clinical Affairs, Medical Study, and Regulatory groups at DermTech in our mission to improve the lives of tens of millions by delivering non-invasive precision dermatology options that empower individualized treatment,” said Dr. Clarke. “DermTech’s breakthrough know-how is shifting the diagnostic pathway to be significantly less invasive, extra precise, and significantly less high priced than the recent pathway of surgical biopsy and histopathology. I seem forward to contributing to DermTech’s achievement in this up coming period of growth.”

Ray Bassi joins DermTech with over 25 a long time of experience in the pharmaceutical and health care unit industry. Prior to signing up for DermTech, Ray served as Vice President, Product sales at Dermira, Inc. where by he led the product sales business in the commercial start in the Dermatology place.

“I’m thrilled to have Ray sign up for the crew and leverage his expertise to guide our discipline income, revenue functions, and profits coaching and growth teams as we execute on our business advancement system,” commented Todd Wooden, main industrial officer of DermTech.

Prior to becoming a member of Dermira, Inc., Ray served as Vice President, Income at Allergan Professional medical, as perfectly as other income management, revenue, and marketing and advertising roles in which he served build significant effectiveness groups, markets, and models. Ray’s sector practical experience contains healthcare dermatology, health-related aesthetics, neuroscience, cardiology, and orthopedics. Ray attained an MBA from Chapman College and a Bachelor of Science diploma in Economics from the University of California, Riverside.

Patrick Johnson joins DermTech from Poseida Therapeutics where he was the Head of Information Know-how. In excess of the earlier thirteen decades, Patrick has held different management positions at Organovo, Inc., DJO Worldwide, Inc., and United Wellness Group, and has extensive encounter creating out main infrastructure, safety courses, and technological know-how procedures and answers to make sure accomplishment at scale. Patrick earned a Bachelor of Science degree in Business Administration from Menlo Faculty.

“DermTech is at a essential phase in our expansion where we’re standing up technology abilities the two for inner scale, as effectively as in aid of essential company initiatives in telemedicine and our direct-to-customer featuring, Luminate,” commented Kevin Sun, main fiscal officer of DermTech. “Patrick’s leadership and the group he’s developing out are important to delivering this strong foundation for our foreseeable future.”

About DermTech:

DermTech is the primary genomics enterprise in dermatology and is making a new classification of drugs, precision dermatology, enabled by our non-invasive pores and skin genomics platform. DermTech’s mission is to change dermatology with our non-invasive pores and skin genomics platform, to democratize obtain to significant excellent dermatology treatment, and to boost the life of millions. DermTech supplies genomic evaluation of skin samples gathered non-invasively applying an adhesive patch fairly than a scalpel. DermTech markets and develops solutions that aid the early detection of skin cancers, and is developing products that evaluate inflammatory diseases and personalize drug treatment options. For additional details on DermTech, please stop by DermTech’s trader relations web page at: www.dermtech.com.

Ahead-Looking Statements:

This press launch consists of “forward-on the lookout statements” in the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech could differ from its actual effects and as a result, you should really not rely on these forward-seeking statements as predictions of upcoming gatherings. Text such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and identical expressions are meant to discover this kind of forward-seeking statements. These forward-on the lookout statements involve, devoid of limitation, expectations with respect to: the efficiency, affected person rewards, cost‑effectiveness, commercialization and adoption of DermTech’s solutions and the industry chance therefor. These ahead-seeking statements include considerable hazards and uncertainties that could bring about the true results to vary materially from the expected effects. Most of these variables are exterior of the command of DermTech and are difficult to predict. Components that may possibly induce these kinds of dissimilarities consist of, but are not limited to: (1) the end result of any lawful proceedings that may well be instituted versus DermTech (2) DermTech’s skill to acquire more funding to build and marketplace its solutions (3) the existence of favorable or unfavorable scientific suggestions for DermTech’s checks (4) the reimbursement of DermTech’s checks by Medicare and personal payors (5) the potential of clients or health care providers to receive coverage of or enough reimbursement for DermTech’s items (6) DermTech’s skill to grow, deal with development and retain its crucial workforce (7) adjustments in relevant legislation or regulations (8) the current market adoption and demand from customers for DermTech’s products and solutions and companies jointly with the probability that DermTech may perhaps be adversely affected by other economic, business, and/or aggressive elements and (9) other threats and uncertainties bundled in (x) the “Risk Factors” portion of the most recent Quarterly Report on Sort 10-Q submitted by DermTech with the Securities and Trade Commission (the “SEC”), and (y) other files submitted or to be submitted by DermTech with the SEC. DermTech cautions that the foregoing list of aspects is not exceptional. You ought to not put undue reliance upon any ahead-searching statements, which communicate only as of the day produced. DermTech does not undertake or acknowledge any obligation or endeavor to release publicly any updates or revisions to any ahead-on the lookout statements to mirror any change in its anticipations or any improve in situations, situations, or conditions on which any these assertion is dependent.